Both vertebrates and anopheline mosquitoes inhibit <i>Plasmodium</i> spp. (malaria parasite) development via induction of nitric oxide (·NO) synthase. Expression of <i>Anopheles stephensi</i> ·NO synthase (<i>AsNOS</i>) is induced in the midgut epithelium beginning at 6 h following a <i>Plasmodium berghei</i>-infected blood meal. ·NO reacts readily with other biocompounds forming a variety of reactive nitrogen intermediates (RNIs) that may impose a nitrosative stress. These RNIs are proposed to be responsible for the AsNOS-dependent inhibition of <i>Plasmodium</i> development. In my studies, I identified several RNIs that are induced in the blood-filled midgut in response to <i>Plasmodium</i> infection. Stable end products of ·NO (NO₃⁻ and NO₂⁻), measured using a modified Griess assay, are elevated in infected midguts at 24 h post-blood meal (pBM). Further studies using chemical reduction-chemiluminescence with Hg displacement showed that infected midguts contained elevated levels of potentially toxic higher oxides of nitrogen (NO<SUB>x</SUB>), but <i>S</i>-nitrosothiol (SNO) and nitrite levels did not differ between infected and uninfected midguts at 12.5 and 24 h pBM. Thus, nitrates contributed to elevated NO<SUB>x</SUB> levels. SNO-biotin switch westerns indicated that <i>S</i>-nitrosated midgut proteins change over the course of blood meal digestion, but not in response to infection. Photolysis-chemiluminescence was used to release and detect bound ·NO from compounds in blood-filled midguts dissected from 0-33 h pBM. Results showed increased ·NO levels in <i>Plasmodium</i>-infected midgut lysates beginning at 8 h, with significant increases at 12.5-13.5 h and 24-25.5 h pBM and peak levels at 20-24 h. Photolyzed ·NO is derived from SNOs and metal nitrosyls. Since SNO concentrations did not change in response to infection, I proposed that metal nitrosyls, specifically Fe nitrosyl hemoglobin (nitrosylHb) based on the concentration of hemoglobin, were elevated in the infected midgut. At 12-24 h pBM, levels of midgut RNIs in infected mosquitoes were typical of levels measured during mammalian septic inflammation. The inverse relationship between AsNOS activity and parasite abundance indicates that nitrosative stress has a detrimental effect on parasite development. However, nitrosative stress may impact mosquito tissues as well in a manner analogous to mammalian tissue damage during inflammation. Elevated levels of nitrotyrosine (NTYR), a marker for nitrosative stress in many mammalian disease states, were detected in tissues of parasite-infected <i>A. stephensi</i> at 24 h pBM. Greater nitration of tyrosine residues was detected in the blood bolus, midgut epithelium, eggs and fat body. In the midgut, Hb remained in an oxygenated state for the duration of blood digestion. The reaction between ·NO and oxyhemoglobin (oxyHb) can result in the formation of nitrate and methemoglobin (metHb). Although nitrate levels were elevated in response to parasite infection, there was little to no metHb present in the mosquito midgut. The simultaneous presence of nitrates, nitrosylHb, oxyHb, and NTYR, together with a lack of elevated nitrites and metHb, suggested that alternative reaction mechanisms involving â ¢NO had occurred in the reducing environment of the midgut. In addition, I proposed that nitroxyl and peroxynitrite participated in reactions that yielded observed midgut RNIs. To cope with the parasite-induced nitrosative stress, cellular defenses in the mosquito may be induced to minimize self damage. I proposed that peroxiredoxins (Prx), enzymes that can detoxify peroxides and peroxynitrite, may protect <i>A. stephensi</i> from nitrosative stress. Six Prx genes were identified in the <i>A. gambiae</i> genome based on homology with known <i>D. melanogaster</i> Prxs. I identified one <i>A. stephensi</i> Prx, AsPrx, that shared 78% amino acid identity with a <i>D. melanogaster</i> 2-Cys Prx known to protect fly cells against various oxidative stresses. <i>AsPrx</i> was expressed in the midgut epithelium and is encoded by a single-copy, intronless gene. Quantitative RT-PCR analyses confirmed that induction of <i>AsPrx</i> expression in the midgut was correlated with malaria parasite infection and nitrosative stress. To determine whether AsPrx could protect against RNI- and ROS-mediated cell death, transient transfection protocols were established for AsPrx overexpression in <i>D. melanogaster</i> (S2) and <i>A. stephensi</i> (MSQ43) cells and for <i>AsPrx</i> gene silencing using RNA interference in MSQ43 cells. Viability assays in MSQ43 cells showed that AsPrx conferred protection against hydrogen peroxide, ·NO, nitroxyl and peroxynitrite. These data suggested that the ·NO-mediated defense response is toxic to both host and parasite. However, AsPrx may shift the balance in favor of the mosquito. / Ph. D.

Experiments were conducted to evaluate nitric oxide (NO) involvement in the leptin effect on food intake in both broiler and Leghorn chickens. The first experiment studied the effect of leptin combined with L-arginine on the food intake in broilers. Intracerebroventricular (ICV) administration of human recombinant leptin injection decreased (P=.01) food intake from 15 to 150 minutes compared to the control group treated with artificial cerebrospinal fluid ( aCSF) while food intake was increased by L-arginine. Food intake between the group receiving leptin and L-arginine was similar to the control group. Therefore, broilers were sensitive to the anoregenic effects of leptin, while L-arginine, a NO precursor appeared to attenuate the leptin effect on food intake. The effect of leptin and L-NNA on food intake in broilers was measured in the second experiment. Lepin, L-NNA and leptin plus L-NNA decreased food intake. The NO inhibitor L-NNA tended to enhance the suppression of leptin on food intake. In the third experiment, using Leghorns instead of broilers, the ICV injection of leptin decreased food intake from 15 to 60 minutes postinjection (P=.05). However, food intake was not affected by injection of L-arginine plus leptin. Therefore, L-arginine appeared to antagonize the leptin inhibitory effect on food intake. A small increase food intake induced by L-arginine was also observed (P=.09). The change of food intake in Leghorns administered leptin and L-NNA were measured in Experiment 4. Food intake was decreased by L-NNA and leptin with the effects lasting 60 minutes, similar to that observed in broilers (P<0.0l). For group B (leptin treatment), there was decreased food intake within 45 minutes (P=.04) and the effect disappeared 60 minutes, post injection. Also, the results along with Experiment 2 demonstrated that NO mediated the effect of leptin in Leghorns. The fifth experiment investigated the change in concentration of metabolites of nitric oxide after injection of leptin within 30 minutes. The group treated with the leptin had a lower level of metabolites of nitric oxide in the hypothalamus than the control group (P=.004). This effect further demonstrates that leptin modulated feeding activity through its inhibition on nNOS activity in the hypothalamus. These results showed that both leptin and NO participated in the regulation of food intake in broiler and Leghorn chickens, and the effect of hypothalamic neuropeptidergic circuitry leptin on food intake was mediated by NO. / Master of Science

Conventional measurements of NO and NO₂ produced by a diffusion flame around a cotton ball wetted by heptane have been performed and prove that NO is oxidized to NO₂ on a mole for mole basis when the air of the flame is doped with hydrogen and that the NO to NO₂ mechanism does not require carbon atoms in the dopant. In-situ spectroscopic measurements of NO in a laminar H₂-air diffusion flame were performed and compared to data obtained with probe sampling procedures. Ultraviolet absorption of the (1,0) gamma bands of nitric oxide near 214.8 nm were used for the spectroscopy. Spectroscopic measurements were possible only when the air stream was seeded with ca. 100 ppm NO. A conventional sampling system was operated at a probe pressure of 0.3 atmosphere and was used to sample from both the high temperature combustion zone and relatively cool regions on both sides of the flame. Spectroscopic and probe measurements of NO agree to within 30%, with probe concentrations being greater. The air of the flame was doped to give 1200 ppm methane and the NO concentrations were measured again, using probe and spectroscopic techniques. Both techniques confirm that even small unburned hydrocarbon concentrations cause the disappearance of NO on the air side of the visible reaction zone. / Master of Science

No / Summary. Background: Endothelial nitric oxide synthase (eNOS) activity in endothelial cells is regulated by post-translational phosphorylation of critical serine, threonine and tyrosine residues in response to a variety of stimuli. However, the post-translational regulation of eNOS in platelets is poorly defined. Objectives: We investigated the role of tyrosine phosphorylation in the regulation of platelet eNOS activity. Methods: Tyrosine phosphorylation of eNOS and interaction with the tyrosine phosphatase SHP-1 were investigated by coimmunoprecipitation and immunoblotting. An in vitro immunoassay was used to determine eNOS activity together with the contribution of protein tyrosine phosphorylation. Results: We found platelet eNOS was tyrosine phosphorylated under basal conditions. Thrombin induced a dose- and time-dependent increase in eNOS activity without altering overall level of tyrosine phosphorylation, although we did observe evidence of minor tyrosine dephosphorylation. In vitro tyrosine dephosphorylation of platelet eNOS using a recombinant protein tyrosine phosphatase enhanced thrombin-induced activity compared to thrombin alone, but had no effect on endothelial eNOS activity either at basal or after stimulation with bradykinin. Having shown that dephosphorylation could modulate platelet eNOS activity we examined the role of potential protein phosphatases important for platelet eNOS activity. We found SHP-1 protein tyrosine phosphatase, co-associated with platelet eNOS in resting platelets, but does not associate with eNOS in endothelial cells. Stimulation of platelets with thrombin increased SHP-1 association with eNOS, while inhibition of SHP-1 abolished the ability of thrombin to induce elevated eNOS activity. Conclusions: Our data suggest a novel role for tyrosine dephosphorylation in platelet eNOS activation, which may be mediated by SHP-1.

Nitric oxide (NO) is a minor species in the Earth’s atmosphere whose densities have been measured to closely reflect solar energy deposition above 100 km. It is an efficient emitter in the infrared where the thermosphere is optically thin, and serves as an important source of radiative cooling between 100 - 200 km. The primary mechanism of this cooling involves the conversion of kinetic energy from the background atmosphere into vibrational energy in NO, followed by the radiative de-excitation of the NO molecule. This results in the production of a 5.3 µm photon which escapes the thermosphere and results in a net cooling of the region. While this process causes the excitation of ground state NO to its first vibrational level, nascent vibrational excitation to the (v≥ 1) levels may also occur from the reactions that produce NO in the thermosphere. The NO(v≥ 1) molecules produced from this secondary process can undergo a radiative cascade and emit multiple photons, thus forming a significant fraction of the 5.3 µm emission from NO in the thermosphere. Existing thermospheric models consider the collisional excitation of NO to be the only source of the 5.3 µm emission and assume the contribution from nascent excitation to be negligible. These models also tend to use a rate coefficient for the collisional excitation that is significantly larger than the values suggested in literature in order to obtain a temperature profile that is in agreement with empirical data. We address these discrepancies by presenting an updated calculation of the chemically produced emission by accounting for the v ≤ 10 level populations. By incorporating this process into a three dimensional global upper atmospheric model, it is shown that the additional emission contributes between 5 − 40% of the daytime emission from nitric oxide under quiet solar conditions, and is a significant source of energy loss during periods of enhanced solar energy deposition. Accounting for this process however does not resolve the model-data discrepancy seen with regards to the recovery times of thermospheric densities following geomagnetic storms, suggesting that an improved treatment of nitric oxide chemistry is required to resolve this issue. In order to improve our understanding of the thermospheric energy budget, we also develop the Atmospheric Chemistry and Energetics (ACE) 1D model using up-to-date aeronomic results. The model self-consistently solves the 1D momentum and energy equations to produce a global average profile of the coupled thermosphere and ionosphere system in terms of its constituent densities and temperatures. The model calculations of neutral densities and exospheric temperatures are found to be in good agreement with empirical data for a wide range of solar activity. It is concluded from the present work that while the magnitude of the chemically produced emission from nitric oxide has previously been underestimated, its effect on the thermospheric energy budget is relatively small. Including the secondary emission in thermospheric models results in an average reduction of 3% in the exospheric temperatures, which does not completely offset the change introduced by using a smaller rate coefficient for the collisional excitation of NO. However, thermospheric temperatures can still be accurately modeled by including these changes as part of broader improvements to calculations of the thermospheric energy budget. / Ph. D. / Nitric oxide (NO) is a molecule that is produced in the Earth’s thermosphere (the region of the atmosphere above 100 kilometers) as a consequence of solar energy deposition. As an important source of radiative cooling, its presence significantly influences the temperature structure of the region. An accurate understanding of the associated energetics is thus vital towards the development of numerical models used to describe the thermosphere. Energy loss from the thermosphere due to nitric oxide begins with the vibrational excitation of the molecule either due to collisions or chemical processes, followed by the emission of one or more infrared photons which returns the molecule to the ground state. The photons produced escape the thermosphere resulting in a net energy loss from this region of the atmosphere. Existing thermospheric models generally account for the vibrational excitation of nitric oxide only via collisions, and have assumed chemical processes to be a negligible source of thermospheric energy loss. These models also assume a rate of collisional excitation that is significantly larger than the values suggested in literature in order to obtain a temperature profile that is in agreement with empirical data. The present work demonstrates that the chemical excitation in fact contributes to between 5 − 40% of the total energy loss due to nitric oxide under quiet solar conditions on the dayside of the Earth, and is also an important energy loss mechanism during periods of enhanced solar activity. However, including this mechanism into existing models does not resolve outstanding model-data discrepancies regarding the rate at which the thermosphere returns to equilibrium following sudden enhancements in solar energy deposition. This suggests the need for an improved treatment of the nitric oxide chemistry in current thermospheric models. This work also presents the Atmospheric Chemistry and Energetics (ACE) 1D model, a new one dimensional upper atmospheric model developed in order to obtain a better understanding of the thermospheric energy budget. The model includes the effects of the chemically produced emissions from nitric oxide, and also uses a collisional cooling rate that is in line with the value suggested in literature. The model calculations of thermospheric densities and temperatures are shown to be in good agreement with empirical data over a wide range of solar activity.

The design of new, improved NO-donor drugs is an important pharmacological objective due to the biological importance of nitric oxide. N-Hydroxyguanidines represent a useful class of NO donors where the mechanism of action is based on the biosynthetic pathway for NO. Thirty new N-arylalkyl-N’-hydroxyguanidines were synthesized and their vasodilatation activity examined by myography in rat aortic rings. The observed relaxations were reversed by ODQ, which is an inhibitor of the guanylate cyclase, implying that this was an NO dependent vasodilatation. The most active compounds were also tested in the isolated perfused kidney (IPK) giving the vasodilatation properties. Preliminary results indicated that N-phenyl-N’- hydroxyguanidine showed the best pharmacological profile with EC₅₀= 19.9 μM and ca. 100% reversibility with ODQ. A series of N-phenylalkyl-N’-hydroxyguanidines were synthesised. NO donor activity was found to be fairly constant up to three methylene groups, and then decreased. Substitutions in the benzene ring of N-phenylethyl-N’-hydroxyguanidine demonstrated that various electron-withdrawing and electron-donating groups in the para position did not significantly affect the NO donor activity of this series of analogues. The nitro and trifluoromethyl substituted compounds gave the best biological profiles. Additionally, a novel heterocyclic, N–furfuryl-N’–hydroxyguanidine possessed very promising vasodilatation properties. In general, almost all the N-arylalkyl-N’-hydroxyguanidines behaved as potent NO donors in the rat aorta assay. In order to establish the influence of the free NH₂ group in the hydroxyguanidine functionality on the vasodilatation properties, N,N-dimethyl and N-methyl-N’- hydroxyguanidines were successfully synthesised. Unfortunately, they have not been tested yet in the biological assay. However, their NMR spectra showed some unusual features and their detailed analysis and X-ray data are presented herein. In addition a series of hydroxamic acids was synthesised and the NO donor activity investigated using the same biological methodology. It was found that the 3-phenylpropionohydroxamic acid was the most potent compound with EC₅₀ = 6 μM and ODQ = 96%. However, behavior in the IPK indicated that hydroxamic acids did not undergo the same biological pathway as in the rat aorta. Two different types of enzyme-activated pro-drugs were designed using N-hydroxyguanidines as the NO donating molecule. Synthetic studies towards these targets were carried out using various synthetic approaches. The desired molecules have not yet been synthesised but the chemistry explored so far has indicated potentially more successful approaches that could be attempted.

Master of Science / Department of Kinesiology / B.J. Wong / Recent data suggests nNOS mediates the NO-component of reflex cutaneous vasodilation with passive heat stress. Our hypothesis was nNOS, but not eNOS, inhibition would attenuate reflex cutaneous vasodilation during dynamic exercise. Protocol 1: subjects performed a VO[subscript]2 peak test on a supine cycle ergometer. Protocol 2: with experimental arm at heart level subjects cycled in supine posture at 60% VO[subscript]2 peak to raise core temperature (Tc) 0.8-1.0°C (35-45 min). In protocol 2 subjects were equipped with 4 microdialysis fibers on the forearm and each randomly assigned as: 1) lactated Ringer’s (control); 2) 5mM NPLA (nNOS inhibition); 3) 10mM L-NIO (eNOS inhibition); and 4) 20mM L-NAME (non- selective NOS inhibition). At the end of protocol 2 all sites were locally heated to 43°C and infused with SNP to elicit maximal dilation. Mean arterial pressure (MAP), skin blood flow via laser- Doppler flowmetry (LDF), and Tc via ingestible telemetric pill were measured; cutaneous vascular conductance (CVC) was calculated as LDF/MAP and normalized to maximum. In protocol 2 there was no significant difference between control (62±5 %CVCmax) and NPLA (61±6 %CVCmax). L-NIO (38±4 %CVCmax) and L-NAME (41±7 %CVCmax) significantly attenuated CVC compared to control and NPLA (p<0.001 all conditions). There was no difference between L-NIO and L- NAME. We conclude eNOS, not nNOS, contributes to reflex cutaneous vasodilation during dynamic exercise.

O óxido nítrico (NO) é o principal agente vasodilatador endógeno que regula o tônus e a homeostase vascular. Dentre os compostos doadores de NO, estão os complexos nitrosilos de rutênio. No presente estudo, o doador de NO estudado, RuBPY, não apresenta citotoxicidade para células do músculo liso vascular (MLV) ao contrário do NPS. O RuBPY apresenta eficácia semelhante ao NPS em relaxar o MLV de aorta de ratos, porém o NPS é mais potente. Ambos compostos liberam NO do tipo radicalar (NO) no meio intracelular, mas o NPS libera também íon nitroxil (NO-). O sequestrador da espécie NO (hidroxocobalamina) reduziu mais a resposta relaxante estimulada com RuBPY do que com o NPS. Nenhum dos dois compostos precisa ser reduzido quimicamente para liberar NO, uma vez que houve relaxamento quando utilizamos alta concentração de KCl como agente contrátil. Porém, este relaxamento foi inibido, o que mostra a importância dos canais para K+ no relaxamento induzido pelos doadores de NO. O bloqueador não seletivo de canais para K+ (TEA), inibiu somente o relaxamento ao RuBPY. A via NO-GCs-GK é ativada por ambos doadores de NO, para induzir relaxamento. A inibição da degradação do GMPc potencializou o relaxamento estimulado com RuBPY e NPS. O armazenamento de Ca+2 no retículo sarcoplasmático (RS) via ativação da SERCA é importante somente para o relaxamento induzido com RuBPY. O composto RuBPY inibiu a resposta contrátil estimulada com fenilefrina devido ao armazenamento de Ca+2 no RS e também por inibir o influxo capacitivo de Ca+2. A presença do endotélio vascular não alterou o relaxamento induzido pelo RuBPY, porém potencializou o relaxamento induzido pelo NPS. A análise da liberação de NO por amperometria demonstrou que o RuBPY libera NO somente em presença do tecido aórtico de ratos. Portanto, não houve liberação espontânea de NO, por fotólise pela luz visível ou por redução química. É necessária a presença de heme-proteínas como a guanilil-ciclase solúvel (GCs) inibida pelo ODQ, para haver a conversão do nitrito presente no RuBPY, a NO. Pela quantificação da fluorescência emitida pela sonda DAF-2DA, RuBPY liberou cerca de 3,5 vezes mais NO do que o NPS. Pela medida do potencial de membrana, demonstramos que o RuBPY induz hiperpolarização de membrana de células isoladas do MLV da aorta de rato. RuBPY tem efeito hipotensor dose-dependente, em ratos hipertensos renais, o que não ocorre em animais normotensos. A redução da pressão arterial em ratos hipertensos é maior do que nos normotensos. Em estudos iniciais de farmacocinética, verificamos que o composto RuBPY é absorvido por via oral e é distribuído entre alguns tecidos após ser administrado aos ratos, por gavagem. / Nitric oxide (NO) is the main endogenous vasodilator agent that regulates vascular tone. Among the compounds which are able of releasing NO, are the nitrosyl ruthenium complexes. The NO donor studied, RuBPY, does not present cytotoxicity in smooth muscle cells (SMC), in contrast to SNP. RuBPY has similar efficacy to SNP in inducing rat aorta relaxation, although SNP is more potent. Both compounds release intracellular radicalar NO (NO), and SNP also release ion nitroxyl (NO-). The NO scavenger (hydroxocobalamine) had greater effect on the relaxation induced by RuBPY than by SNP. Both compounds do not need to be chemically reduced to release NO, as demonstrated in aorta relaxation after pre-contraction with high concentrations of KCl. However, this relaxation was impaired, showing the importance of K+ channels to induce relaxation by NO released from these compounds. By using non-selective blocker for K+ channels (TEA), only the relaxation induced by RuBPY was inhibited. The NO-sGC-GK pathway is activated by NO donors to induce relaxation. Inhibition of cGMP degradation, potentiated the effect of RuBPY and SNP. Storage of Ca+2 in the sarcoplasmic reticulum (SR) via activation of SERCA is important only for the relaxation induced by RuBPY. The contractile response induced by phenylephrine was inhibited by RuBPY due to the storage of Ca+2 in RS and also by inhibiting the capacitive influx of Ca+2. The presence of endothelium had no effect on the relaxation induced by RuBPY, but it potentiated the relaxation induced by SNP. RuBPY released NO only in the presence of the rat aorta. The complex RuBPY did not spontaneously release NO, by photolysis by visible light, or by chemical reduction. RuBPY requires the presence of heme-protein such as guanylyl-cyclase, inhibited by ODQ, to convert nitrite to NO. The amount of NO released from RuBPY was about 3.5 times greater than that released from SNP. RuBPY induced membrane hyperpolarization of SMC. RuBPY has hypotensive effect in renal hypertensive rats in a dose-dependent way, which does not occur in normotensive rats. The decreased of blood pressure in hypertensive rats was greater than in normotensive rats. Initial studies of pharmacokinetics demonstrated that RuBPY is orally absorbed and it is also distributed in some tissues after being administered by gavage to rats.

Xue, Hongmei. / "December 2010." / Thesis (Ph.D.)--Chinese University of Hong Kong, 2011. / Includes bibliographical references (leaves 165-206). / Electronic reproduction. Hong Kong : Chinese University of Hong Kong, [2012] System requirements: Adobe Acrobat Reader. Available via World Wide Web. / Abstract also in Chinese.

Yip Kwok Ho. / Thesis (M.Phil.)--Chinese University of Hong Kong, 2006. / Includes bibliographical references (leaves 231-260). / Abstracts in English and Chinese. / Abstract (English) --- p.i / Abstract (Chinese) --- p.iv / Acknowledgements --- p.vi / Publications --- p.vii / Abbreviations --- p.viii / Contents --- p.xi / Chapter 1. --- Introduction --- p.1 / Chapter 1.1. --- Mast cells --- p.2 / Chapter 1.2. --- "Mast cell origin, growth and development" --- p.2 / Chapter 1.2.1. --- Stem cell factor --- p.4 / Chapter 1.2.2. --- Interleukins --- p.6 / Chapter 1.3. --- Mast ceII heterogeneity --- p.7 / Chapter 1.4. --- Mast ceII mediators --- p.9 / Chapter 1.4.1. --- Pre-Synthesized mediators --- p.9 / Chapter 1.4.1.1. --- Histamine --- p.10 / Chapter 1.4.1.2. --- Protease --- p.11 / Chapter 1.4.2. --- Newly synthesized mediators --- p.13 / Chapter 1.4.2.1. --- Prostanoid --- p.14 / Chapter 1.4.2.2. --- Cysteinyl Leukotriene --- p.15 / Chapter 1.4.3. --- Mast cell-derived cytokines and growth factors --- p.16 / Chapter 1.5. --- Mast cell activation --- p.17 / Chapter 1.5.1. --- FceRI-dependent mast cell activation --- p.18 / Chapter 1.5.1.1. --- FceRI and IgE aggregation --- p.19 / Chapter 1.5.1.2. --- Protein-tyrosine kinase activation --- p.21 / Chapter 1.5.1.3. --- Phospholipase activation and calcium ion mobilization --- p.22 / Chapter 1.5.1.4. --- GTPase and MAPK activation --- p.24 / Chapter 1.5.2. --- Non-immunogical mast cell activation --- p.26 / Chapter 1.6. --- Roles of mast cell in inflammatory disease --- p.27 / Chapter 1.7. --- Nitric oxide --- p.28 / Chapter 1.8. --- Nitric oxide synthase --- p.30 / Chapter 1.9. --- Nitric oxide signaling in cellular level --- p.31 / Chapter 1.9.1. --- Direct effects of NO --- p.32 / Chapter 1.9.2. --- Indirect effects of NO --- p.34 / Chapter 1.10. --- Mast cell and nitric oxide --- p.35 / Chapter 1.11. --- Aim of Study --- p.37 / Chapter 2. --- Materials and Methods --- p.43 / Chapter 2.1. --- Material --- p.44 / Chapter 2.1.1. --- Human buffy coat for mast cell culture --- p.44 / Chapter 2.1.2. --- Materials for cell isolation and cell counting --- p.44 / Chapter 2.1.3. --- Materials for mast cell culture --- p.45 / Chapter 2.1.4. --- Material for buffers --- p.45 / Chapter 2.1.5. --- Materials for cytospin and May-Griinwald-Giemsa staining --- p.46 / Chapter 2.1.6. --- Materials for immunocytochemical staining --- p.46 / Chapter 2.1.7. --- Mast cell secretagogues --- p.47 / Chapter 2.1.8. --- Nitric oxide donors --- p.47 / Chapter 2.1.9. --- Soluble Guanylyl Cyclase activators and cGMP analogues --- p.47 / Chapter 2.1.10. --- Drugs involved in NO-sGC-cGMP pathway --- p.48 / Chapter 2.1.11. --- Materials for histamine assay --- p.48 / Chapter 2.1.12. --- Materials for Enzyme Immunosorbent Assay (EIA) --- p.49 / Chapter 2.1.13. --- Pro-inflammatory cytokines --- p.49 / Chapter 2.1.14. --- Materials for RNA extraction and RT-PCR --- p.49 / Chapter 2.1.15. --- Materials for Immunofluorescence staining --- p.50 / Chapter 2.1.16. --- Anti-asthmatic compounds --- p.51 / Chapter 2.1.17. --- Buffer and stock solution --- p.51 / Chapter 2.1.17.1. --- Buffer ingredients --- p.51 / Chapter 2.1.17.2. --- Stock solution --- p.52 / Chapter 2.2. --- Methods --- p.52 / Chapter 2.2.1. --- CD34+ cell isolation from human buffy coat --- p.52 / Chapter 2.2.2. --- CD34+ cell culture --- p.53 / Chapter 2.2.3. --- Human mast cell line (HMC-1 cells) culture --- p.54 / Chapter 2.2.4. --- Mast cell heterogeneity identification --- p.54 / Chapter 2.2.4.1. --- Cell smear preparation --- p.54 / Chapter 2.2.4.2. --- May-Gruwald-Giemsa staining --- p.55 / Chapter 2.2.4.3. --- Immunocytochemical staining --- p.55 / Chapter 2.2.5. --- Histamine release and measurement --- p.56 / Chapter 2.2.5.1. --- Histamine release --- p.56 / Chapter 2.2.5.2. --- Spectroflurometric determination of histamine content --- p.57 / Chapter 2.2.5.3. --- Calculation of histamine level --- p.57 / Chapter 2.2.6. --- Prostaglandin D2 (PGD2) measurement --- p.58 / Chapter 2.2.6.1. --- PGD2 production --- p.58 / Chapter 2.2.6.2. --- EIA methods for PGD2 measurement --- p.58 / Chapter 2.2.6.3. --- Calculation of PGD2 concentration --- p.59 / Chapter 2.2.7. --- Cysteinyl Leukotrienes (Cys-LTs) measurement --- p.59 / Chapter 2.2.7.1. --- Cys-LTs production --- p.59 / Chapter 2.2.7.2. --- EIA methods for Cys-LTs measurement --- p.60 / Chapter 2.2.7.3. --- Calculation of Cys-LTs concentration --- p.60 / Chapter 2.2.8. --- Tumor necrosis factor-alpha (TNF-α) measurement --- p.61 / Chapter 2.2.8.1. --- TNF-α production --- p.61 / Chapter 2.2.8.2. --- EIA methods for TNF-α measurement --- p.61 / Chapter 2.2.8.3. --- Calculation of TNF-α concentration --- p.62 / Chapter 2.2.9. --- Interleukin-8 (IL-8) measurement --- p.62 / Chapter 2.2.9.1. --- IL-8 production --- p.62 / Chapter 2.2.9.2. --- ELISA for IL-8 measurement --- p.62 / Chapter 2.2.9.3. --- Calculation of IL-8 concentration --- p.63 / Chapter 2.2.10. --- Data presentation --- p.63 / Chapter 2.2.11. --- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) --- p.64 / Chapter 2.2.11.1. --- RNA extraction --- p.64 / Chapter 2.2.11.2. --- Reverse Transcriptase reaction for cDNA synthesis --- p.65 / Chapter 2.2.11.3. --- Polymerase Chain Reaction --- p.66 / Chapter 2.2.11.4. --- Agarose Gel Electrophoresis --- p.67 / Chapter 2.2.11.5. --- Data representation in RT-PCR experiment --- p.67 / Chapter 2.2.12. --- Immunofluorescence staining --- p.67 / Chapter 2.2.12.1. --- Cell smear preparation --- p.68 / Chapter 2.2.12.2. --- Immunofluorescence staining --- p.68 / Chapter 2.3. --- Statistical analysis --- p.69 / Chapter 3. --- Effect of Nitric Oxide Donors on Mast Cell Activation --- p.70 / Chapter 3.1. --- Introduction --- p.71 / Chapter 3.1.1. --- Mechanisms of NO release from NO donors --- p.71 / Chapter 3.1.2. --- Experimental aims --- p.77 / Chapter 3.2. --- Materials and methods --- p.77 / Chapter 3.3. --- Results --- p.78 / Chapter 3.3.1. --- Development of mast cells from buffy coat --- p.78 / Chapter 3.3.2. --- Morphological features of cultured mast cells --- p.78 / Chapter 3.3.3. --- Phenotype of cultured mast cells --- p.79 / Chapter 3.3.4. --- Effects of NO donors on immunologically stimulated mediators release --- p.79 / Chapter 3.3.4.1. --- SIN-1 and NOR-3 --- p.80 / Chapter 3.3.4.2. --- SNP and SNAP --- p.80 / Chapter 3.3.4.3. --- Diazeniumdiolates (NONOates) --- p.80 / Chapter 3.3.5. --- Effects of NO scavenger on NO donors mediated inhibition of immunologically stimulated mediators release --- p.82 / Chapter 3.3.6. --- Discussion --- p.83 / Chapter 4. --- Interaction between NO donors and pharmacological agentsin modulating mast cell activation --- p.123 / Chapter 4.1. --- Introduction --- p.124 / Chapter 4.1.1. --- Modulators of NO-sGC-cGMP pathway --- p.125 / Chapter 4.1.2. --- Anti-asthmatic compounds --- p.128 / Chapter 4.1.3. --- Experimental aims --- p.130 / Chapter 4.2. --- Materials and methods --- p.131 / Chapter 4.3. --- Results --- p.132 / Chapter 4.3.1. --- Effect of sGC activators on immunologically stimulated histamine release and the inhibitory action of DEA/NO --- p.132 / Chapter 4.3.2. --- Effect of cGMP analog on immunologically stimulated histamine release --- p.133 / Chapter 4.3.3. --- "Effects of the sGC inhibitor, ODQ, on DEA/NO induced inhibition on immunologically stimulated mediators release" --- p.134 / Chapter 4.3.4. --- Effects of anti-oxidants on the actions of NO donors in modulating immunologically stimulated mediators release --- p.134 / Chapter 4.3.5. --- The effects of NO donors on salbutamol mediated inhibition of immunologically stimulated histamine release from human mast cells --- p.135 / Chapter 4.3.6. --- The effects of NO donors on theophylline mediated inhibition of immunologically stimulated histamine release from human mast cells --- p.136 / Chapter 4.3.7. --- The effects of NO donors and DSCG on immunologically stimulated histamine release from human mast cells --- p.137 / Chapter 4.4. --- Discussion --- p.137 / Chapter 4.5. --- Further studies --- p.150 / Chapter 5. --- Human mast cells as a source of nitric oxide --- p.178 / Chapter 5.1. --- Introduction --- p.179 / Chapter 5.1.1. --- Nitric oxide synthases expression in mast cell --- p.180 / Chapter 5.1.2. --- Modulation of NOS expression --- p.182 / Chapter 5.1.3. --- Experimental aims --- p.186 / Chapter 5.2. --- Materials and methods --- p.186 / Chapter 5.3. --- Results --- p.187 / Chapter 5.3.1. --- NOS expression in human mast cell-line HMC-1 --- p.187 / Chapter 5.3.1.1. --- Basal --- p.187 / Chapter 5.3.1.2. --- Effect of cytokines --- p.188 / Chapter 5.3.2. --- NOS expression in cultured CD34+ derived human mast cells --- p.189 / Chapter 5.3.2.1. --- Basal --- p.189 / Chapter 5.3.2.2. --- Effect of cytokines --- p.189 / Chapter 5.3.2.3. --- Effect ofIgE and anti-IgE --- p.190 / Chapter 5.4. --- Discussion --- p.191 / Chapter 5.5. --- Further studies --- p.200 / Chapter 6. --- Conclusion --- p.218 / Chapter 7. --- References --- p.230